Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Molecular Mechanism of Asthma

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00180726
First received: September 13, 2005
Last updated: August 12, 2008
Last verified: August 2008
  Purpose

The aim of this study is to investigate the mechanisms whereby lung function is decreased in asthma and sensitivity to treatment. The hypothesis is that in diseases such as asthma, inflammatory cells (leukocytes) including eosinophils, macrophages and lymphocytes migrate to the lung and release either more or different types of inflammatory mediators and/or receptors compared to subjects without asthma, which are corticoid sensitive or insensitive. The objective of the study is to identify which genes are specifically expressed in important cells in patients with asthma with a view to identify novel targets for drug therapy.


Condition Intervention
Asthma
Procedure: Blood sampling, Endoscopic Bronchoscopy, Spirometry

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Regulation of Inflammatory Mediators in Asthma

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • gene expression evaluated using mRNA

Secondary Outcome Measures:
  • corticosteroid sensitivity

Estimated Enrollment: 30
Study Start Date: December 2003
Estimated Study Completion Date: July 2007
Detailed Description:

We aim to investigate these separate cell types in the blood of subjects with asthma and identify which genes are more highly expressed when compared to cells obtained from patients without asthma. We will investigate corticosteroid sensitivity on gene expression in asthma (corticoid naive to corticosteroid resistant asthma). We will also investigate the lung cells (macrophages) from these subjects to identify whether the same or different genes are expressed in these cells.

We will isolate different leukocyte populations from the blood and extract ribonucleic acid (RNA) from these samples. The type and quantity of RNA in these samples is a reflection of the specific genes expressed in these cells. Gene expression is also evaluated by ELISA.This RNA will be sent to Gene Logic in the USA and this company will test these samples to identify which genes have been expressed using Gene Arrays. This technique will examine the expression of all 33,000 human genes in each sample to examine activation of interacting pathways rather than individual genes at a time. Samples will be analysed in the USA and preliminary data shows that there are no problems involving sample transportation or degradation.

Similar experiments will be performed using cells (macrophages) obtained following bronchoalveolar lavage of these subjects. We would aim to examine the responses of cells from two groups of subjects, namely (i) non-asthmatics controls and (ii) asthmatic subjects. The isolated cells will either be immediately solubilized in solutions to purify RNA or we will then use these isolated cells in vitro and following stimulation investigate whether different genes are expressed or at a differential rate in the disease state. We will examine both cells derived from peripheral blood and cells (macrophages) obtained from bronchoalveolar lavage with the aim to determine whether differences attributable to disease can be identified in both circulating cells and those at the site of disease.

This is a preliminary study to determine the profile of inflammatory mediator expression from leukocytes and as such power calculations to determine the number of subjects is not appropriate.

The objective of the study is to identify which genes are specifically expressed in important cells in patients with asthma with a view to identify novel targets for drug therapy.

  Eligibility

Ages Eligible for Study:   21 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Asthmatic Patients

  1. Stable asthmatics on beta-2 agonist alone not using more than 4 puffs per day
  2. Atopic as defined by positive skin prick tests to at least 2 common aeroallergens
  3. PC20 methacholine of < 4 mg /ml
  4. Increase in FEV1 > 15% following beta-2 agonist inhalation, either at the time of study or previously documented
  5. Age 21-55 years of both sexes (females will be taking adequate contraceptive measures)
  6. Non-smokers
  7. Normal chest x-ray (CXR) and electrocardiogram (ECG) within the last 6 months.

Healthy Non-Asthmatic Subjects

All normal volunteers will meet the following criteria:

  1. Age 21-70 years of both sexes (females will be taking adequate contraceptive measures)
  2. No history of respiratory or allergic disease e.g. PC20 methacholine of > 64mg/ml and negative skin prick tests
  3. Non-atopic with negative skin prick tests to common aeroallergens
  4. Normal baseline spirometry as predicted for age, sex and height.
  5. Non-smokers
  6. Not taking regular medication
  7. No upper respiratory tract infection within the last 6 weeks

Exclusion Criteria:

Subjects will not be included in this study if they meet any of the following exclusion criteria:

  1. Clinically significant findings in the medical history or on physical examination other than those of asthma in the asthma group.
  2. Lung function FEV1 <30%
  3. Pregnant women or mothers who are breastfeeding.
  4. Patients who smoke
  5. Upper respiratory infection within the last 4 weeks
  6. Allergy to local anaesthetic
  7. Subjects who are unable to give informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180726

Locations
United Kingdom
Airway Disease, NHLI, Imperial College
London, United Kingdom, SW3 6LY
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Ian M Adcock, PhD NHLI, Imperial College
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00180726     History of Changes
Other Study ID Numbers: NHLI-MB-1
Study First Received: September 13, 2005
Last Updated: August 12, 2008
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:
asthma, inflammatory, corticosteroid

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 20, 2014